Navigation Links
Metformin's Anti-Cancer Properties Clarified in an Obesity Cell Model of Pancreatic Cancer
Date:7/22/2013

Los Angeles, California (PRWEB) July 22, 2013

SiDMAP, LLC, a leading provider of targeted 13C tracer fate association studies and biomarker development services, announces the publication of findings that metformin inhibits carbon flux towards new fatty acid synthesis in the presence of cholesterol, a known diseases factor in obesity and diabetes, to facilitate pancreatic cancer growth. The integrated nutritional and 13C Isotopolome-Wide Association Study with cholesterol administration to pancreatic cancer cell lines, is published in the official journal of the Metabolomics Society in collaboration with scientists at the University of Arizona, Department of Nutritional Sciences and the University of Arizona Cancer Center.

SiDMAP scientists provided the metabolic analysis for the study using pancreatic cancer cells expressing K-ras differently, which is a common mutation in pancreatic cancer. They integrated positional 13C labeling in multiple metabolic products in diverse sampling sites from a single 13C labeled glucose tracer. It is known that stable expression of K-ras induces a pancreatic cancer metabolic phenotype that competes for new acetate, formed from glucose, in the cholesterol and fatty acid producing pathways. “Cholesterol administration diverts new acetate towards fatty acid synthesis, which provides the contextual factor for metformin to inhibit new fatty acid synthesis, cell membrane turnover and potentially cell growth,” said Dr. Laszlo G. Boros, Chief Scientist at SiDMAP.

“The study may explain the mechanism of how elevated circulating cholesterol, which is an important disease modifying factor in the diabetic pancreatic cancer patient, alters cellular metabolism in a way that metformin’s known fatty acid synthase inhibiting effect becomes a cell growth limiting factor,” said Dr. Emmanuelle J. Meuillet, the study’s lead investigator.

The work is published as a Springer Open Access article, online first, in the journal Metabolomics and is titled, “Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells.” http://link.springer.com/article/10.1007%2Fs11306-013-0555-4

The study was supported by the Hirshberg Foundation for Pancreatic Cancer Research (http://www.pancreatic.org). “It is a key goal of the Foundation to bring lead scientists together to shed light on well-known, yet unexplained disease controlling mechanism of national research interest in obesity, diabetes and pancreatic cancer. This research is significant because it is in line with the National Cancer Institute’s quest to find bold new approaches to answer the perplexing scientific question of why the mechanism of a drug like metformin, which is generally used for other indications, protects against cancer incidence and mortality,“ said Agi Hirshberg, President of the Foundation.

About SiDMAP
SiDMAP provides flux-based, metabolic profiling services to pharmaceutical, biotech and research organizations seeking to enhance their drug development processes, and develop further insights into a drug’s mechanism of action and disease states. SiDMAP’s unique tracer technology measures metabolic pathway flux to gain unique insights into cell function. A SiDMAP assay provides clients with an accurate, dynamic metabolic analysis of a compound’s biological impact in both in vitro and in vivo systems, before a company spends millions more on development and clinical trials. SiDMAP is headquartered in Los Angeles, California.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10947481.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New understanding of why anti-cancer therapy stops working at a specific stage
2. Anti-cancer drug viewed as possible Alzheimers treatment doesnt work in UF study
3. Overcoming resistance to anti-cancer drugs by targeting cell powerhouses
4. Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
5. Development of the first way to make large amounts of promising anti-cancer substance
6. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
7. Specialized MRI scans assess value of anti-cancer chemotherapy long before tumors shown to shrink
8. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Patent Issued for Apparel and Textile Fabric with Antimicrobial Properties
11. New studies explore mangos potential health-affirming properties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology: